Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

References

• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239(1):27-44; PMID:21198663; https://doi.org/10.1111/j.1600-065X.2010.00979.x
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39(1):1-10; PMID:23890059; https://doi.org/10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39(1):38-48; PMID:23890062; https://doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 2001; 166(9):5327-30; PMID:11313367; https://doi.org/10.4049/jimmunol.166.9.5327
   PubMed Web of Science ®Google Scholar
• Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207(6):1283-92; PMID:20479118; https://doi.org/10.1084/jem.20100223
   PubMed Web of Science ®Google Scholar
• Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207(6):1261-71; PMID:20479117; https://doi.org/10.1084/jem.20092618
   PubMed Web of Science ®Google Scholar
• Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008; 118(6):2098-110; PMID:18497879; https://doi.org/10.1172/JCI34584
   PubMed Web of Science ®Google Scholar
• Paulis LE, Mandal S, Kreutz M, Figdor CG. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol 2013; 25(3):389-95; PMID:23571027; https://doi.org/10.1016/j.coi.2013.03.001
   PubMed Web of Science ®Google Scholar
• Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C. Targeted delivery of a-galactosylceramide to CD8a+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol 2014; 193(2):961-9; PMID:24913977; https://doi.org/10.4049/jimmunol.1303029
   PubMed Web of Science ®Google Scholar
• Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol 2014; 44(7):1947-55; PMID:24648154; https://doi.org/10.1002/eji.201344076
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6(232):232ra51; PMID:24739759; https://doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Vega-Ramos J, Villadangos JA. Consequences of direct and indirect activation of dendritic cells on antigen presentation: functional implications and clinical considerations. Mol Immunol 2013; 55(2):175-8; PMID:23200227; https://doi.org/10.1016/j.molimm.2012.10.034
   PubMed Web of Science ®Google Scholar
• Wiesel M, Oxenius A. From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help. Eur J Immunol 2012; 42(5):1080-8; PMID:22539281; https://doi.org/10.1002/eji.201142205
   PubMed Web of Science ®Google Scholar
• Silva JM, Videira M, Gaspar R, Préat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013; 168(2):179-99; PMID:23524187; https://doi.org/10.1016/j.jconrel.2013.03.010
   PubMed Web of Science ®Google Scholar
• Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 2016; 28(7):329-38; PMID:27006304; https://doi.org/10.1093/intimm/dxw015
   PubMed Web of Science ®Google Scholar
• Aarntzen EHJG, Bol K, Schreibelt G, Jacobs JFM, Lesterhuis WJ, Van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72(23):6102-10; PMID:23010076; https://doi.org/10.1158/0008-5472.CAN-12-2479
   PubMed Web of Science ®Google Scholar
• Neumann S, Young K, Compton B, Anderson R, Painter G, Hook S. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression. Vaccine 2015; 33(43):5838-44; PMID:26363382; https://doi.org/10.1016/j.vaccine.2015.08.083
   PubMed Web of Science ®Google Scholar
• Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007; 25:297-336; PMID:17150027; https://doi.org/10.1146/annurev.immunol.25.022106.141711
   PubMed Web of Science ®Google Scholar
• Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9(1):28-38; PMID:19079136; https://doi.org/10.1038/nri2451
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13(2):101-17; PMID:23334244; https://doi.org/10.1038/nri3369
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171(10):5140-7; PMID:14607913; https://doi.org/10.4049/jimmunol.171.10.5140
   PubMed Web of Science ®Google Scholar
• Fujii S-I, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198(2):267-79; PMID:12874260; https://doi.org/10.1084/jem.20030324
   PubMed Web of Science ®Google Scholar
• Stober D, Jomantaite I, Schirmbeck R, Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 2003; 170(5):2540-8; PMID:12594280; https://doi.org/10.4049/jimmunol.170.5.2540
   PubMed Web of Science ®Google Scholar
• Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 2010; 11(4):313-20; PMID:20190758; https://doi.org/10.1038/ni.1848
   PubMed Web of Science ®Google Scholar
• Tullett KM, Lahoud MH, Radford KJ. Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy. Front Immunol. 2014; 5:239; PMID:24904587; https://doi.org/10.3389/fimmu.2014.00239
   PubMed Web of Science ®Google Scholar
• Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182(5):2816-26; PMID:19234176; https://doi.org/10.4049/jimmunol.0803648
   PubMed Web of Science ®Google Scholar
• Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10–producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Inves 2014; 124(9):3725-40; https://doi.org/10.1172/JCI72308
   PubMed Web of Science ®Google Scholar
• Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS One 2013; 8(11):e80063; PMID:24244610; https://doi.org/10.1371/journal.pone.0080063
   PubMed Web of Science ®Google Scholar
• Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207(6):1273-81; PMID:20479115; https://doi.org/10.1084/jem.20100348
   PubMed Web of Science ®Google Scholar
• Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167(7):4046-50; PMID:11564825; https://doi.org/10.4049/jimmunol.167.7.4046
   PubMed Web of Science ®Google Scholar
• Molling JW, Kölgen W, van der Vliet HJJ, Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005; 116(1):87-93; PMID:15756674; https://doi.org/10.1002/ijc.20998
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011; 140(2):160-6; PMID:21233022; https://doi.org/10.1016/j.clim.2010.12.010
   PubMed Web of Science ®Google Scholar
• Exley MA, Nakayama T. NKT-cell-based immunotherapies in clinical trials. Clin Immunol 2011; 140(2):117-8; PMID:21592864; https://doi.org/10.1016/j.clim.2011.04.015
   PubMed Web of Science ®Google Scholar
• Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182(4):2492-501; PMID:19201905; https://doi.org/10.4049/jimmunol.0800126
   PubMed Web of Science ®Google Scholar
• Schneiders FL, Scheper RJ, von Blomberg BME, Woltman AM, Janssen HL, van den Eertwegh AJ, Verheul HM, de Gruijl TD, van der Vliet HJ. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011; 140(2):130-41; PMID:21169066; https://doi.org/10.1016/j.clim.2010.11.010
   PubMed Web of Science ®Google Scholar
• Hunn MK, Hermans IF. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. Oncoimmunology 2013; 2(4):e23789; PMID:23734325; https://doi.org/10.4161/onci.23789
   PubMed Web of Science ®Google Scholar
• Dölen Y, Kreutz M, Gileadi U, Tel J, Vasaturo A, van Dinther EAW, van Hout-Kuijer MA, Cerundolo V, Figdor CG. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. Oncoimmunology 2015; 5(1):e1068493; PMID:26942088; https://doi.org/10.1080/2162402X.2015.1068493
   PubMed Web of Science ®Google Scholar
• Silva AL, Soema PC, Slütter B, Ossendorp F, Jiskoot W. PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccines Immunother 2016; 12(4):1056-69; https://doi.org/10.1080/21645515.2015.1117714
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand KJ, Salio M, Cerundolo V. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 2007; 178(5):2721-9; PMID:17312114; https://doi.org/10.4049/jimmunol.178.5.2721
   PubMed Web of Science ®Google Scholar
• Dong T, Yi T, Yang M, Lin S, Li W, Xu X, Hu J, Jia L, Hong X, Niu W. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Biochem J 2016; 473(1):7-19; PMID:26450924; https://doi.org/10.1042/BJ20150129
   PubMed Web of Science ®Google Scholar
• Coelho-Dos-Reis JG, Huang J, Tsao T, Pereira FV, Funakoshi R, Nakajima H, Sugiyama H, Tsuji M. Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells. Clin Immunol 2016; 168:6-15; PMID:27132023; https://doi.org/10.1016/j.clim.2016.04.014
   PubMed Web of Science ®Google Scholar
• Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh TP, Sanchez C, Savoret J, Perrot I, et al. Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. J Immunol 2014; 193(4):1622-35; PMID:25009205; https://doi.org/10.4049/jimmunol.1401243
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138(3):255-65; PMID:21185787; https://doi.org/10.1016/j.clim.2010.11.014
   PubMed Web of Science ®Google Scholar
• Kitayama S, Zhang R, Liu TY, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, et al. Cellular adjuvant properties, direct cytotoxicity of Re-differentiated Vα24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Rep 2016; 6(2):213-27; https://doi.org/10.1016/j.stemcr.2016.01.005
   PubMed Web of Science ®Google Scholar
• Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo TA, Kitahara G, Okoshi M, Kobayashi M, Sakurai M, et al. Efficient regeneration of human V1537;24(+) invariant natural killer T cells and their anti-tumor activity in vivo. Stem Cells 2016; 34(12):2852-60; PMID:27422351; https://doi.org/10.1002/stem.2465
   PubMed Web of Science ®Google Scholar
• Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997; 6(4):469-77; PMID:9133426; https://doi.org/10.1016/S1074-7613(00)80290-3
   PubMed Web of Science ®Google Scholar
• Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997; 278(5343):1623-6; PMID:9374462; https://doi.org/10.1126/science.278.5343.1623
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008; 322(5904):1097-100; PMID:19008445; https://doi.org/10.1126/science.1164206
   PubMed Web of Science ®Google Scholar
• Bouabe H, Liu Y, Moser M, Bösl MR, Heesemann J. Novel highly sensitive IL-10-beta-lactamase reporter mouse reveals cells of the innate immune system as a substantial source of IL-10 in vivo. J Immunol 2011; 187(6):3165-76; PMID:21844394; https://doi.org/10.4049/jimmunol.1101477
   PubMed Web of Science ®Google Scholar
• Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and Proinflammatory CD8+ T Lymphocytes Promote Development of Vulnerable Atherosclerotic Plaques in ApoE-Deficient Mice. Circulation 2013; 127(9):1028-39; PMID:23395974; https://doi.org/10.1161/CIRCULATIONAHA.112.001347
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010; 144(2):118-26; PMID:20156497; https://doi.org/10.1016/j.jconrel.2010.02.013
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers M, Eich C, de Vries IJ, Figdor CG. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol Pharm 2011; 8(2):520-31; PMID:21381651; https://doi.org/10.1021/mp100356k
   PubMed Web of Science ®Google Scholar
• Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt G, Figdor CG, de Vries IJ. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol 2013; 191(10):5005-12; PMID:24127556; https://doi.org/10.4049/jimmunol.1300787
   PubMed Web of Science ®Google Scholar
• Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, Borsellino G, Dellabona P, Bonneville M, Scotet E et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood 2007; 110(1):251-8; PMID:17363727; https://doi.org/10.1182/blood-2007-01-066217
   PubMed Web of Science ®Google Scholar